Ethno-epidemiology of HCV, HIV and Overdose associated with Drug Markets and Drug Tourism

多样性补充摘要 拟议的多样性补充文件旨在通过以下方式促进科学界的多样性： Samantha Schiavon，M.A.，一位拉丁裔临床心理学家， 在弱势群体和种族/少数民族人群中进行疾病治疗研究。斯齐亚冯女士 通过她在医学/临床心理学的博士前培训获得了强大的研究背景 博士课程在伯明翰的亚拉巴马大学，并将继续推进她的研究 作为加州圣地亚哥大学（UCSD）的博士后研究员，他的能力。通过这个 作为补充，Schiavon女士将通过研究污名化对妇女的影响来建立她的研究能力。 注射吸毒者开始使用阿片类药物治疗阿片类药物使用障碍的动机 她将在Steffanie Strathdee博士（小学）的指导下接受培训 导师和PI家长补助金），一个世界著名的传染病流行病学家，专注于艾滋病毒 托马斯帕特森博士（共同导师），以他的艾滋病毒/艾滋病研究而闻名。 沿着墨西哥-美国边境地区的预防干预措施，以及拉勒米史密斯博士（共同导师），一位专家， 艾滋病患者污名化研究。通过二级数据分析，本补编将扩大以下目标： 父母补助金，以确定墨西哥和美国之间的跨文化差异在MOUD和实质 使用疾病污名作为PWID中MOUD治疗开始意图的潜在障碍。具体 目的是：1）审查主要居住国（墨西哥诉美国）作为预期之间的调节剂 物质使用障碍的耻辱感和开始MOUD治疗的意图; 2）评估 预期的MOUD处理（即，（丁丙诺啡/丁丙诺啡与美沙酮） 居住（墨西哥诉美国）;和3）检查预期的MOUD耻辱作为国家之间的调解人， 主要居住地（墨西哥诉美国）和MOUD治疗启动意向。这些结果将告知 制定文化上敏感的干预措施，以减少作为MOUD治疗启动障碍的污名化 并将作为斯齐亚冯女士未来K23提案的基础。因此，该补充不会 只提供关键的支持，以加强女士Schiavon的培训，在她的博士后奖学金在 UCSD，但也将促进她通过K23成为一名独立的临床研究人员的过渡 该奖项的重点是减少国际PWID人群中MOUD治疗启动的障碍。

Abstract of Diversity Supplement The proposed Diversity Supplement is designed to promote diversity in the scientific community through the training of Samantha Schiavon, M.A., a Latinx clinical psychologist with experience conducting substance use disorder treatment research among vulnerable and racial/ethnic minority populations. Ms. Schiavon has obtained a strong research background through her pre-doctoral training in the Medical/Clinical Psychology Doctoral Program at the University of Alabama at Birmingham and will continue to advance her research competencies as a research postdoctoral fellow at the University of California San Diego (UCSD). Through this supplement, Ms. Schiavon will build her research capacities through examining the impact of stigma on motivations to initiate medication for opioid use disorder (MOUD) treatment among persons who inject drugs (PWID) within Mexico and the U.S. She will train under the mentorship of Dr. Steffanie Strathdee (primary mentor and PI on parent grant), a world-renowned infectious disease epidemiologist focused on HIV prevention research in developing countries, Dr. Thomas Patterson (co-mentor), known for his HIV/AIDS prevention interventions along the Mexico-U.S. border region, and Dr. Laramie Smith (co-mentor), an expert in stigma research among PWID. Through secondary data analysis, this supplement will expand upon the aims of the parent grant to identify cross-cultural differences between Mexico and the U.S. in MOUD and substance use disorder stigma as potential barriers to MOUD treatment initiation intentions among PWID. The specific aims are to: 1) to examine country of primary residence (Mexico v. US) as a moderator between anticipated substance use disorder stigma and intentions to initiate MOUD treatment; 2) to assess differences in anticipated MOUD treatment (i.e., buprenorphine/suboxone vs. methadone) stigma by country of primary residence (Mexico v. US); and 3) to examine anticipated MOUD stigma as a mediator between country of primary residence (Mexico v. US) and MOUD treatment initiation intentions. These results will inform the development of culturally responsive interventions to reduce stigma as a barrier to MOUD treatment initiation and will serve as the foundation for Ms. Schiavon’s future K23 proposal. Therefore, this supplement will not only provide crucial support to enhance Ms. Schiavon’s training throughout her postdoctoral fellowship at UCSD, but will also facilitate her transition to becoming an independent clinical researcher through a K23 award focused on reducing barriers to MOUD treatment initiation among international populations of PWID.